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The incidence of cancer increases with advanced age. And as the world population ages, clinicians will be faced with a
growing number of older patients with cancer. The challenge that clinicians face involves carefully choosing the type
of therapeutic care plan that is most appropriate given a person’s level of physical reserve, medical comorbidities, and
psychosocial resources. Inclusion of assessment tools in clinical practice such as a comprehensive geriatric assessment
can assist clinicians in identifying patients who will benefit from aggressive cancer care or palliative measures. The role
of palliative care, especially in the frail older patient, is critical in improving quality of life. Improvement in best care
practices in older patients with cancer requires their inclusion in clinical trials.
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The incidence of cancer increases dramatically with age.
Current statistics show that about 50% of cancers diag-
nosed in the United States occur in people over the age of
65 and this is expected to rise to 70% by 2030. The inci-
dence of cancer is reported to be 12 to 36 times higher in
patients 65 years or older compared with those aged 25 to
44 years, and 2 to 3 times higher in individuals 45 to 64
years of age. Mortality is also higher in older patients, ac-
counting for nearly 70% of cancer deaths per year [1]. The
challenge for cancer specialists is to determine the
optimum treatment for elderly patients, a heterogeneous
population in terms of comorbidity, disability, physical re-
serve, and other geriatric conditions. Best treatment prac-
tices for older patients with cancer are lacking, in part due
to sub-optimal or excessively toxic treatments and under-
representation in clinical trials, resulting in poorer out-
comes compared with younger patients. Issues that impact
oncologic and supportive care management unique to the
geriatric population will be highlighted in this article.Discussion
Aging is defined as a progressive loss of a person’s entropy
and fractal organization that limits the functional reserve
of multiple organ systems and the ability to withstand
stress. Such changes bring about reduced life expectancy,* Correspondence: mdelacruz@mdanderson.org
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article, unless otherwise stated.increased susceptibility to disease and loss of personal in-
dependence. The process of aging varies from person to
person. Some patients undergo successful aging, where ro-
bust physical and cognitive abilities are maintained
throughout life [2]. There are those described as having
frailty, which is characterized by weakness and decreased
functional reserve [3,4]. Physiologic age does not corres-
pond to a person’s chronologic age and is more clinically
useful in medical decision-making. Determination of
physiologic age is largely based on a comprehensive geriat-
ric assessment (CGA). This multi-dimensional method in-
corporates functional status, comorbidities, cognition,
nutrition, medications, and social support structures. It as-
sists clinicians to better estimate life expectancy and func-
tional reserve, which are relevant in treatment-related
decisions. The use of the CGA also allows for identifica-
tion of frailty and other unrecognized conditions that can
influence management.
The older patient diagnosed with cancer can present
with various other problems, making evaluation of treat-
ment options for cancer more complex. Besides consid-
eration of cancer-related factors, assessment of other
aspects of a patient’s health status including social, func-
tional, cognitive, economic and spiritual domains, is cru-
cial in developing a treatment plan that is tailored to
individual needs. Since the mid-1990s, oncologists and
geriatricians have sought to integrate the use of CGA in
the oncologic setting, hoping to assist clinicians in for-
mulating optimal therapeutic plans. Components of the
CGA have been shown to not only affect life expectancyd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tom burden. Box 1 lists questions that can affect thera-
peutic choices and measure treatment efficacy and guide
in planning care for the elderly [5].Box 1 Questions to ask in deciding therapeutic care
plan for the elderly cancer patient [6]
Is the patient going to die of cancer or with cancer?
Is the patient going to live long enough to suffer the
consequences of cancer?
Is the patient able to tolerate the treatment?
What are the long term consequences of cancer treatment in
the elderly?
Will any treatment improve the quality of life?
What are the patient’s goals of care?
Is the social network of the patient adequate to support
him/her during the treatment?Frailty is a concept that is becoming increasingly used
to describe patients with reduced reserve in multiple
organ systems resulting in increased risk of disability or
death with minor stresses. Functionally, these patients
are characterized as having a wasting syndrome; low en-
ergy, gait speed and grip strength; many chronic medical
comorbidities; complex psychosocial problems; signifi-
cant risk of dependency; and other adverse health out-
comes [7-9]. Cancer and its treatment are substantial
stressors that diminish physiological reserves, so the
concept of frailty is particularly pertinent for older pa-
tients with cancer. On the basis of the frailty phenotype,
optimal management strategies for treatment and inclu-
sion in clinical trials may be achieved through patient
stratification. Table 1 shows Fried’s criteria for frailty [8].
Fit geriatric patients are good candidates for almost the
same type of cancer treatment as younger patients andTable 1 Fried’s frailty criteria1 [7]
Abnormalities Frailty scale
Involuntary weight loss of 10 lbs or
more in the last 6 months
Fit (no abnormalities)
Reduced grip strength Pre-frail (2 abnormalities or less)
Difficulty initiating movements Frail (3 or more abnormalities)
Reduced walking speed
Fatigue
1. Categories of Frailty:
Fit: No abnormalities.
Pre-Frail: 2 abnormalities or less.
Frail: 3 or more abnormalities.have similar survival outcomes. Patients who are frail
would benefit from more palliative approaches to treat-
ment [8], with the assumption that their functional re-
serve is so poor that they will not be able to tolerate even
minimal stress that may arise from therapeutic regimens.
Those who fall in between are more problematic and
would require individualization of treatment approach.
Frailty has rarely been measured in patients with can-
cer. Some evidence shows that frailty is present in youn-
ger patients with cancer, and can even be observed in
cancer survivors. This indicates that familiarity and un-
derstanding of the concept of frailty is essential from the
time of consideration of treatment to cure and subse-
quent follow-ups. Most older adults with cancer will fall
into the pre-frail and frail category, therefore it is im-
portant that supportive care measures be made available
to them. This requires access to palliative care services
to manage symptoms that may arise from the burden of
disease as well as the adverse effects of cancer treatment.
The interdisciplinary team that is central to the practice
of palliative care is most useful in the geriatric patient.
These patients will benefit from specialized care en-
compassing multiple domains for improved quality of
life. Quantifying frailty can help reduce futile and bur-
densome interventions that are not expected to improve
symptoms or those that may worsen function and qual-
ity of life. Frailty assessment is therefore essential for the
timely delivery of holistic palliative care in geriatric pa-
tients with progressive and terminal disease [10].
With the aging of the population and the known asso-
ciation between cancer and older age, inclusion of older
geriatric patients in clinical trials has been advocated by
several experts. The under-representation of this at-risk
population has been highlighted by several authors [11].
It has been proposed that exclusion in studies is related
to reduced function, presence of comorbidities, con-
comitant medications, lack of access, and poor social
support. Proposals to improve participation of older
adults include clinical trials specifically designed for
older adults with multiple comorbidities, trials with dos-
ing regimens tailored for older patients, standardized
use of geriatric tools, and alternative end points or out-
comes [12-14]. Data from 2001 to 2010 showed that 24
drugs were approved by the US Food and Drug Admin-
istration for cancer treatment and only 33% of patients
that were registered in those trials were 65 years or older
[15]. This is a dismal representation given that 59% of
patients with cancer during the same time period were
of this age group [16]. The problem with non-inclusion
is that evidence-based treatment recommendations are
not always applicable to the older patient, particularly
those who are vulnerable and frail. In addition, those in-
cluded in the trials are not representative of the majority
of older adults with cancer. Designing protocols tailored
de la Cruz and Bruera BMC Medicine 2013, 11:218 Page 3 of 3
http://www.biomedcentral.com/1741-7015/11/218to include older patients should be specially designed to
avoid under-representation. The CGA can be used as a
tool that can classify patients fit to receive certain spe-
cific treatments other than using age and clinical judg-
ment as the sole basis for treatment decisions. Such
clinical trials would be helpful in guiding appropriate pa-
tient selection, risk stratification, and toxicity evaluation.
Conclusion
The incidence of cancer rises with increasing age.
Specialists who care for cancer patients face the diffi-
culty in identifying optimum treatment options for eld-
erly patients. The concept of frailty and the use of the
CGA help guide treatment decisions, enabling clinicians
to better identify the presence of comorbidities and geri-
atric syndromes, and the level of physical reserve or dis-
ability. Incorporating supportive care measures early in
these patients, particularly those who fall into the pre-
frail and frail categories of the frailty index, is crucial to
successful management. Future cancer and palliative
care research should be more inclusive of this popula-
tion. Specially designed protocols for older adults are ne-
cessary to provide more appropriate evidence-based
approaches to cancer treatment in geriatrics.
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